Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

3 clinical trials; the ability of the Natural History Staggered Start trial design and trial analysis methodology to provide the same level of disease modification support as the cross-over trial designs; the ability of the Natural History Staggered Start trial design and trial analysis methodology to demonstrate that this trial analysis methodology is mathematically equivalent to the "Staggered Start" and "Randomized Withdrawal" designs and provides the same level of evidence of a disease modifying drug effect in a clinical trial that is not subject to the complications, bias and ethical challenges of previous designs; the excitement of the Company about this persuasive mathematical comparison of clinical trial designs and the Company's belief that this mathematical proof, coupled with the Flurizan trial design, may strengthen the Company's position with the FDA in favor of a disease modification label for Flurizan; the successful completion of the ongoing Flurizan Phase 3 trials; and whether the Flurizan Phase 3 trials results will demonstrate or support a claim of disease modification. These forward-looking statements are based on management's current expectation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements. These include, but are not limited to, uncertainties as to the extent of future government regulation of Myriad Genetics' business; uncertainties as to whether Myriad Genetics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutic compounds; the risk that markets will not exist for therapeutic compounds that Myriad Genetics develops or if such markets exist, that Myriad Genetics will not be able to sell compounds, which it develops, at acceptable prices; and the risk that the Company will not be able to sustain revenue growth for its predictive medicine busine
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:5/15/2008)...Showed Acceptable Tolerability Profile, ... WOODCLIFF LAKE, N.J., May 15 /- The ...sylate (E7389) demonstrated activity in a,heavily ...ed or metastatic,breast cancer, according to resul...study also suggests that eribulin mesylate has a m...
(Date:5/15/2008)...ated in Blacks, Hispanics/Latinos, People ...SIPPANY, N.J., May 15 /- Daiichi Sank...he American Society of,Hypertension,s Twenty- Thir...ans demonstrated that the powerful combination dru...afely and effectively helped,patients across sever...
(Date:5/15/2008)... /- Ergonex Pharma today,announced th...(FDA) has,granted orphan drug designation to Tergu...tension (PAH). Terguride is currently being evalua..., "The FDA,s grant of orphan drug designation to ...evelopment program by offering regulatory,clinica...
(Date:5/15/2008)...or an Antiplatelet Therapy that, Combined, with As...f Plavix/Iscover and Aspirin, According to a N..., May 15 /- Decision Resources, one o...for pharmaceutical and,healthcare issues, finds th...vement in patient compared to Sanofi-Aventis/Brist...
Breaking Medicine Technology:Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 1Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 4Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 6032 1Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 6032 2ABR Affinity BioReagents to Exhibit in the U S Pavilion at Medica November 14 17 2007 824 1ABR Affinity BioReagents to Exhibit in the U S Pavilion at Medica November 14 17 2007 824 2Vioxx Settlement Announced 6028 1
..., 2007 - New data show the,investigational drug te...ted with Huntington,s disease (HD) up to 80 weeks ...ment in a 13-week trial.,These data suggest that t...educed chorea burden in long-term use., "These fin...nazine as maintenance therapy for U.S. patients wh...
...RE)--May 4, 2007 - New data from a,randomized, dou...ONE(R) (glatiramer acetate injection) along with t...um (Gd)-enhancing lesions,of the brain by 63 perce...tting multiple sclerosis (RRMS), as measured by,ma...receiving,COPAXONE(R) alone. Additionally, the nin...
Other Medicine Technology:Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
(Date:5/15/2008)...NG, China, May 15 /Xinhua-PRNewswire-FirstCall/ --...lletin Board: GTEC) ("Genesis" or,the "Company"), ...perations,in the People,s Republic of China, today...nded March 31, 2008, the Company,s third quarter o...m was filed for the quarter,with the U.S. Securiti...
(Date:5/15/2008)...nt safety in hospitals focus of 48 NQF-endorsed me.../ -- Recognizing that patient,safety remains a maj...ty,Forum (NQF) today endorsed 48 voluntary consens...of acute care hospitals, including measures,addres...revention and care,of venous thromboembolism., "I...
(Date:5/15/2008)...ab injections every 3 months a more convenient re...Y, May 15 (HealthDay News) -- The drug ustekinumab... long-term treatment for moderate-to-severe psoria...of The Lancet . , Ustekinumab works by binding...une system that mediate inflammatory reactions in ...
(Date:5/15/2008)...TON, D.C. -- May 15, 2008 -- The Society for Card...day announced that it will hold its 2009 Annual Sc..., Las Vegas. The focused, collegial interventional...r early March meeting time beginning in 2010. , ...he premier interventional cardiology meeting of th...
Breaking Medicine News(10 mins):Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 2Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 3Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 4Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 5Health News:Drug Works Well for Moderate-to-Severe Psoriasis 2Health News:SCAI announces 2009 annual scientific sessions in Las Vegas 2
...umber of bus drivers and conductors in India are b...t of the bus conductor Ravindra Kamble (34). //Sta...ctors in the last one year have been tested positi...mme was started by General Manager SS Kshatriya in...
...ia's largest biotechnology firm, has made a paradi... innovation to drive its future growth aggressivel...s API (active pharmaceutical ingredients) manufact...loping a robust pipeline of new molecules. "We be...
...n accused of wasting over ?500m associated with ov...at John Hemming// who cited government figures on ...her added that once the drugs lost their patent, t... prices. The Birmingham Yardley MP blamed the hea...
...s from Denmark, published on bmj.com in February, ...s on a risehas caused a growing concern among doct...e of 22% from 1995 to 2004. They noted that this w... 20-40, where there was a 51% increase in early de...
Other Medicine News:Health News:Biocon To Shift Focus On Innovation To Accelerate Growth 2Health News:More Than ?500m Wasted On Drugs; MP Blames NH 2Health News:Concern Over The Rise In Preterm Deliveries 2
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig
... cross action. Round handle. Divides nucleus for p...ithout grooving. Nuclei of any hardness can be pre...er. Phaco of pre-chopped nuclear fragments is rapi...ving is diminished. Shortened ultra sound time and...
Karate chopper, spear shaped for ease of insertion into the nucleus.
Phaco chopper & iris retractor 2 mm cutting edge.
Medicine Products: